The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund announce a publication in Emerging Microbes & Infections, a peer-reviewed medical journal, sharing the results of a study on intranasally delivered Sputnik V coronavirus vaccine. The study shows this type of the vaccine induces a strong and durable immune response in animals.

The article has been peer-reviewed and is available at:

https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2119169

The intranasal Sputnik V was studied in in mice and in non-human primates (common marmosets). High immunogenic properties of the vaccine were verified by marked IgG and neutralizing antibody (NtAb) production in blood serum, antigen-specific T-cell proliferation and formation of IgA antibodies in the nasal mucosa.

The vaccine induced a robust (no less than 180 days) systemic and local immune response. Study’s findings demonstrate that in the mouse model, intranasal and intramuscular administration of Sputnik V vaccine elicits comparable magnitude of central antigen-specific immunity, while only intranasal vaccination forms humoral and cell-mediated response in lungs.

Lungs are more vulnerable to infection by the novel strains of coronavirus, including BA4 and BA5 sub-strains of Omicron. The ability of intranasal vaccine to elicit protective immunity at the entry gates of infection provided by mucosal vaccination is key to block virus infection and transmission and may become a “silver bullet” that could bring the pandemic to an end.

Intranasal administration of Sputnik V is well-tolerated and effective for developing both local and systemic immune responses, as well as providing protection against lethal virus challenge, which is comparable to that of the initially developed intramuscular vaccine.

An earlier study conducted by a team of Russian scientists including representatives of the City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya Center has demonstrated Sputnik V’s efficacy against hospitalisation caused by Omicron for those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V) was 97% and 99.4% against critical cases. These results have been published in June 2022 in the Vaccines leading peer-reviewed medical journal[i].

Sputnik V is one of the safest and most effective vaccines against coronavirus in the world and has become the most exported pharmaceutical product in the Russian history. The high safety and efficacy of Sputnik V and one-shot Sputnik Light have been confirmed by more than 50 clinical studies and data compiled during national vaccination programs in various parts of the world, including Europe, Asia, the Middle East and Latin America. Research on the Sputnik V vaccine has been published in leading international peer-reviewed medical journals, including The Lancet, Nature, Vaccines, Cell Reports Medicine and others.

The Russian Direct Investment Fund is among the world’s leading sovereign wealth funds with a diversified investment portfolio in key sectors. RDIF has played a leading role in development of a ‘triad’ against coronavirus including test-systems, a drug and the Sputnik V vaccine, which has helped to save millions of lives in more than 30 countries around the world.

RDIF invested in development and production of both Sputnik V and Sputnik Light, which have helped save millions of lives globally. Sputnik V has been authorized in 71 countries with total population of over 4 billion people. Sputnik Light has been approved in more than 30 countries. Sputnik V and Sputnik Light are based on a safe human adenoviral vector platform proven in more than 30 years and are not associated with serious adverse events such as myocarditis or pericarditis.

About Post Author

Admin

vrdyu@pongapandit.in

https://thinknews.today

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

The post The Gamaleya Center study in animals shows the intranasally delivered Sputnik V vaccine induces robust and durable immune response to coronavirus appeared first on Think News Today.

Declared as the winner in the category of ‘CSR in Aspirational Districts / Difficult Terrains’ (Eastern India) and ‘Contribution in National Priority Areas’ (Support to differently-abled) JSP has been selected for this coveted award after a rigorous three-stage selection process initiated by the Ministry based on its prescribed systems of nominations  New Delhi, 22nd August 2022: Adding another feather in its cap, Jindal Steel & Power (JSP) has been selected for the prestigious National CSR Award 2020 in two categories by the Ministry of Corporate Affairs, Government of India.

As per an announcement recently by the Ministry of Corporate Affairs, Jindal Steel & Power, led by Shri Naveen Jindal, has been declared as the winner in the category of ‘CSR in Aspirational Districts / Difficult Terrains’ (Eastern India) and ‘Contribution in National Priority Areas’ (Support to differently-abled). JSP has been selected for this coveted award after a rigorous three-stage selection process initiated by the Ministry based on its prescribed systems of nominations by various Ministries, State Govt, three eminent Professional Institutes in India and Industry & Trade Chambers followed by Field verification and Grand Jury evaluation.

Commenting on the development, Chairman, JSP, Shri Naveen Jindal said, “We at JSP pursue Industry led inclusive development of our Nation partnering with the People and caring for the Planet. We have been implementing multidimensional Social development programmes under our CSR to improve the Quality of Life of the Community sustainably in the geography of our operational locations and beyond. The National CSR Award by the Ministry of Corporate Affair to JSP under two categories is indeed recognition of our philosophy of Passion for People. For us, it is always People First “.

Expressing her gratitude to the Government of India for recognizing Jindal Steel & Power with the National CSR Award, Smt. Shallu Jindal, Chairperson of JSP Foundation said, “We are humbled and encouraged that the Government of India has awarded us the highest recognition for our CSR programmes. As we emerge from the pandemic world, we are more aware of the crisis and needs that we are facing at various levels, in health, education, society and climate.

All our Programmes are completely aligned with the UN Sustainable Development Goals and aim to develop a more equitable and developed balance for the people in this country. This award will continue to motivate us to accelerate our efforts in implementing sustainable and inclusive development programmes across India.”

WADI, one of the innovative projects by JSP reviewed for the National CSR Award is an Agro Horti Silvipasture-based project implemented on 500 acres of hilly land benefiting the tribal populace of Chhattisgarh’s Tamnar block in Raigarh district. Under JSP Foundation’s Project Sneh, JSP has significantly contributed to major reduction of malnutrition in more than 1200 Children in Pallahara block in Angul district of Odisha. Both these interventions were reviewed in the multilayer selection process for the National CSR Award in the category of ‘CSR in Aspirational Districts / Difficult Terrains’ (Eastern India) apart from the Project Vastalya to control IMR and MMR and other projects of women empowerment in the tribal predominant region of Tamnar. Similarly the JSP’s flagship programme ‘Asha the Hope’ was reviewed for the award in the category of ‘Contribution in National Priority Areas’ (Support to differently-abled). Through this project, implemented under the umbrella support of JSP Foundation, the company works for the rehabilitation and empowerment of differently abled, particularly people in the formative age group.

Through its CSR arm JSP Foundation, JSP has been implementing multi-faceted sustainable social development initiatives around its operational areas in Odisha, Chhattisgarh and Jharkhand as well as across India with focus on consistent Improvement of the Human Development Index and associated socio-economic development measures in rural and tribal areas.  This is the announcement of CSR award for 2020 . The awards announced for the very first year of the award in 2019 was delivered by the HE President of India in Vigyan Bhawan , New Delhi.

About Post Author

Admin

vrdyu@pongapandit.in

https://thinknews.today

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

The post Jindal Steel & Power wins prestigious National CSR Award 2020 in ,Two Categories by the Ministry of Corporate Affairs appeared first on Think News Today.

The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund announce the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.

Over the course of the pandemic the Gamaleya Center has been consistently studying the new emerging variants of SARS-CoV-2 and adapting Sputnik V to them accordingly. The new version of Sputnik V has been Delta- and Omicron-adapted as Omicron is currently the dominant variant around the globe. This new version is also addressing the L-452-R mutation in Omicron BA5 variant which was not present in the BA1 variant.

The Delta and Omicron-adapted version of Sputnik V is the most promising version of the vaccine specifically adapted to new variants as compared to those tailored against the combination of the original strain and Omicron variant.

The Sputnik V vaccine adapted against the Delta and Omicron variants provides for a significant reduction in the viral load in the lungs of animals infected with the Omicron BA5 variant.

The existing version of Sputnik V shows excellent results in preventing hospitalization and death caused by Omicron. A study conducted by a team of Russian scientists including representatives of the City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya Center has demonstrated Sputnik V’s efficacy against hospitalisation caused by Omicron for those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V) was 97% and 99.4% against critical cases. These results have been published in June 2022 in the Vaccines leading peer-reviewed medical journalⁱ.

Sputnik V has become the most exported pharmaceutical product in the Russian history being one of the safest and most effective vaccines against coronavirus in the world.

The Russian Direct Investment Fund invested in development and production of both Sputnik V and Sputnik Light, which have helped save millions of lives globally. Sputnik V has been authorized in 71 countries with total population of over 4 billion people. Sputnik Light has been approved in more than 30 countries.

Sputnik V and Sputnik Light are based on a safe human adenoviral vector platform proven  in more than 30 years and are not associated with serious adverse events such as myocarditis or pericarditis. The high safety and efficacy of Sputnik V and Sputnik Light have been confirmed by more than 50 clinical studies and data compiled during national vaccination programs in various parts of the world, including Europe, Asia, the Middle East and Latin America. Research on the Sputnik V vaccine has been published in leading international peer-reviewed medical journals, including The Lancet, Nature, Vaccines, Cell Reports Medicine and others.

About Post Author

Admin

vrdyu@pongapandit.in

https://thinknews.today

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

The post The Gamaleya Center has developed a Delta- and Omicron-adapted Sputnik V vaccine appeared first on Think News Today.

• Five organs were harvested and donated to multiple hospitals to save several lives
• Faith in humanity was restored by the family in showing immense courage and strength in donating the organs
• Marengo CIMS Hospital expresses its heartfelt gratitude to the family who opted for the noble act of organ donation

 In an exemplary heroic and humanitarian act of nobility, a family which lost a young member to brain stroke decided to donate his organs to save several lives. Jayeshbhai Patel aged 35 years, was a factory worker. While working he collapsed and moving through various hospitals, the patient was brought to Marengo CIMS hospital where he was declared “Brain-dead”.

The family rose above their grief and sorrow to embrace humanity and donate the deceased family member’s organs to save four lives and restore the sight of one. One kidney, two lungs, two corneas and one liver were retrieved. Post the retrieval process, the organs were reached to patients over four states. This was a show of immense courage and strength by the family to restore faith in humanity. At Marengo Asia Healthcare, we believe every minute counts, every life matters. The importance of timely decisions taken in organ donation is paramount in contributing significantly to saving lives.

With Marengo CIMS Hospital armed with multiple organ transplant programs such as heart, lungs, kidney, and liver, the hospital is fast emerging as a preferred destination for organ transplants in India.

Dr Raajiv Singhal, Founding Member, MD & CEO, Marengo Asia Healthcare said, “Marengo Asia Healthcare expresses our heartfelt gratitude to the patient’s family who went beyond their intense grief to think of several other patients whose lives could be saved by their act of organ donation. Our gratitude to many more such families who overcome their sorrow to save many lives by donating organs of their deceased family member. Many patients die every year due to lack of organ donation. Organ donation can save 500,000 lives in India each year. When families come forward with such humanitarian act, the fact that organ donation is picking up is reiterated. We encourage people to become a part of such humanitarian acts that can save thousands of lives every year.”

The patient’s family said, “We realized the enormity of the number of lives that could be saved with this simple act of organ donation. We are encouraged by the fact that Jayeshbhai Patel will live through the people who have received his organs.”

With increased organ donation we can save more and more lives. India happens to be one of the top countries in organ transplant in the world and yet, we lag our western counterparts. In India, a huge disparity between demand of organs for saving lives and the organs donated is witnessed consistently. The increasing numbers in organ donation in India is just about picking up, the awareness having been low and other reasons working as deterrents being religious beliefs, spiritual beliefs, and a negative mindset towards organ donation. The recent increase has been an outcome of increased awareness on the noble act.

About Post Author

Admin

vrdyu@pongapandit.in

https://thinknews.today

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

The post Marengo CIMS Hospital deeply acknowledges the exemplary courage of a family that opted to donate organs of their deceased family member to save four lives and restore sight in one appeared first on Think News Today.

Allo Health , India’s first digital health clinic for sexual wellness, announced the appointment of a technology leader Gaurav Gupta, as the CTO. In his new role, Gaurav will be responsible for leading and spearheading new efforts to build the holistic care platform and scaling the business.

Prior to this, Gaurav led the Labs and Billing team at Carbon Health, a chain of modern full-stack primary and urgent care clinics in the USA. Before Carbon, Gaurav was the CTO and Founding engineer at Eligible Inc, New York City, USA. Eligible provides a platform to securely process all insurance billing transactions, which powers some of the most innovative and advanced healthcare providers in the USA. As the CSO and security lead at Eligible, he extensively contributed to building highly available, scalable, reliable, secure, and HIPAA-compliant tech infrastructures. He was also instrumental in category expansion, automation in retail, and monetizing image inventory systems at Amazon. He was also part of the IBM Tivoli Solutions team, where he architected three solutions and published a patent with the US patent Office.

Speaking on the appointment, Pranay Jivrajka, CEO – Allo Health said, “I am thrilled to have Gaurav join the team. His appointment comes at a time when Healthcare technology is rapidly changing the ways patients receive care in India. His experience in building and scaling world-class technology teams will be enormously helpful in creating a user-first platform that makes sexual wellness care accessible to all. Welcoming Gaurav to embrace the new wave of digital care delivery with Allo Health.”

Speaking on his appointment, Gaurav Gupta, CTO, Allo Health said, “Allo Health is revolutionizing the way Sexual wellness care is delivered by bringing doctors, operators, and engineers under one roof. The numerous taboos and discourses associated with sexual wellness in India prevent people from seeking help or even talking about it. We had our first baby through IVF last year, and since then, my wife and I have been raising awareness and breaking taboos associated with fertility treatment. I always wanted to return to India and improve healthcare discovery, delivery, and management here. I am thrilled to be a part of a team working relentlessly to bring a paradigm shift in care delivery through advanced technologies and services. We aim to normalize sexual wellness and make it accessible to all. I am ecstatic to join Allo Health and do my bit in building India’s first digital health clinic for sexual wellness.”

Gaurav’s appointment underscores Allo Health’s mission to normalise sexual wellness for all and make sexual health care delivery accessible to all through technology. He is a graduate of IIT Varanasi with a recognized track record of conceptualising and realising scalable solutions across various industries like Health Tech, E-commerce, Tech Corps to name a few .

About Post Author

Admin

vrdyu@pongapandit.in

https://thinknews.today

Happy

0 0 %

Sad

0 0 %

Excited

0 0 %

Sleepy

0 0 %

Angry

0 0 %

Surprise

0 0 %

The post Allo Health announces appointment of Gaurav Gupta as CTO appeared first on Think News Today.